BMO Capital downgraded Novo Nordisk (NVO) to Market Perform from Outperform with a $64 price target
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- ‘Time to Make a Warren Buffett Move,’ Says Top Investor About Novo Nordisk Stock
- Eli Lilly Stock (LLY) Back in Shape as It Sues Compounders Over Weight-Loss Drugs
- Hims & Hers Stock (HIMS) Dips After FDA Flags Safety Concerns
- Clinical Trial Success Positions Eli Lilly Stock (LLY) for Major Rebound
- Eli Lilly selloff on Novo report more than warranted, says Citi